Amarin axes 120 of its 385 employees, hires new CEO Patrick Holt
AI policymaking needs more voices from healthcare
Lilly’s donanemab flaunts strong clinical profile, ready to compete with Leqembi
Phase III data shows Keytruda's promise in earlier-stage cervical cancer
*please scroll down for all the latest news*